shimony.net
Shimony - Advanced Financial Services - Payroll
http://www.shimony.net/en/customers-en/payroll
Shimony - Advanced Financial Services. Controlling and CFO services team. Bookkeepers and tax consultants. Shimony - Advanced Financial Services, 5 Badner St., Ramat Gan, 5254223, P.O.Box 8241, Ramat Gan 5218102, Tel: 972-3-6116666, Fax: 972-3-6116610. D-webs websites and marketing.
can-fite.com
Can-Fite BioPharma - Home Page
http://www.can-fite.com/index1.aspx
TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases. May 11, 2015. Can-Fite`s Phase II Liver Cancer Trial Approved in Europe. May 4, 2015. Can-Fite subsidiary, OphthaliX, Signs Term Sheet to Acquire Improved Vision Systems Ltd.
ir.stockpr.com
Quote | Can-Fite BioPharma Ltd. (NYSE MKT: CANF)
http://ir.stockpr.com/canfite/quote
Quarterly and Annual Reports. Can-Fite BioPharma's quoted shares on this page are American Depository Receipts (ADRs) which are negotiable certificates issued by a U.S. bank representing a specified number of Can-Fite's ordinary shares which are traded on the Tel Aviv Stock Exchange. The ratio is 1 ADR = 2 ordinary shares. Can-Fite currently has approximately 8.06 million ADRs traded on the NYSE.
shimony.net
Shimony - Advanced Financial Services - Bookkeeping and Controlling
http://www.shimony.net/en/customers-en/bookkeeping-and-accounting
Shimony - Advanced Financial Services. Controlling and CFO services team. Bookkeepers and tax consultants. Shimony - Advanced Financial Services, 5 Badner St., Ramat Gan, 5254223, P.O.Box 8241, Ramat Gan 5218102, Tel: 972-3-6116666, Fax: 972-3-6116610. D-webs websites and marketing.
canfite.co.il
Can-Fite BioPharma - Home Page
http://canfite.co.il/index1.aspx
TASE:CFBI; NYSE MKT:CANF) is an Israeli biopharmaceutical company with fully integrated pharmaceutical discovery and clinical development capabilities. The company has an advanced pipeline of proprietary compounds in phase 2 and 3 clinical development stage, which address autoimmune-inflammatory and cancer diseases. May 11, 2015. Can-Fite`s Phase II Liver Cancer Trial Approved in Europe. May 4, 2015. Can-Fite subsidiary, OphthaliX, Signs Term Sheet to Acquire Improved Vision Systems Ltd.
thelifesciencesreport.com
Can-Fite BioPharma Ltd. CANF:NYSE.MKT
http://www.thelifesciencesreport.com/pub/co/5788
The Life Sciences Report. The Life Sciences Report. Alliance for Regenerative Medicine. Streetwise Reports is registered with the U.S. Patent and Trademark Office. Get our newsletter free. A valid email address is required to subscribe.
ir.canfite.com
All SEC Filings | Can-Fite BioPharma Ltd. (NYSE MKT: CANF)
http://ir.canfite.com/all-sec-filings
Quarterly and Annual Reports. Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments. Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments. Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments. Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments. Prospectus filed pursuant to Rule 424(b)(3). Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 Amendments.
